Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of XW003 in Healthy Adults
NCT04389775Phase 1Completed
- Sponsor
- Sciwind Biosciences
- Start
- Mar 2020
- Primary completion
- Sep 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ecnoglutide in type 2 diabetes mellitus (T2DM), obesity and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Sciwind Biosciences. Primary endpoint: Number of treatment emergent adverse events. Started Mar 2020; status: completed.
02
Drugs
ecnoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04389775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389775.